Dasolon Tablet (Methylprednisolone)

Adult dosage

The initial dose may vary from 4mg to 48mg per day as methylprednisolone, depending on the symptoms of the specific disease. In general, a low dose is sufficient for less severe conditions, although an initially high dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is achieved. If a satisfactory clinical result is not achieved after a reasonable period, treatment should be discontinued and replaced with another appropriate therapy. The dose must be determined individually according to the various diseases being treated and the patient’s response. After an adequate response is achieved, an appropriate maintenance dose should be determined by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. The dose requires continuous monitoring. Situations that may require dosage adjustment include remission or worsening of the disease, individual patient response to the drug, and the effects on the patient of exposure to stressful circumstances unrelated to the symptoms of the disease being treated. In the latter situation, it may be necessary to increase the dose for a period sufficient to provide satisfactory control of the patient’s condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the drug. For treatment of acute exacerbations of multiple sclerosis, administration of prednisolone 200mg daily for 1 week followed by prednisolone 80mg every other day for 1 month is effective (4mg methylprednisolone is equivalent to 5mg prednisolone). Alternate-day therapy means administering twice the daily dose on one morning every 2 days. Although a single morning dose is associated with considerably less adrenal suppression than taking prednisolone (10mg) in 4 divided doses every 6 hours, there is evidence that, when pharmacologic doses are used, some suppression of adrenal activity continues into the following day. For less serious diseases for which corticosteroid therapy is indicated, alternate-day therapy (ADT) may be used initially. For more serious conditions, a divided daily high-dose regimen will usually be required for initial control of disease progression. The initial suppressive dose should be continued until a satisfactory clinical response is achieved, usually for 4 to 10 days in many allergic and collagen diseases. ① Switch to ADT and gradually reduce the amount of corticosteroid given every other day. ② As disease progression comes under control, reduce the daily corticosteroid dose to the minimum effective level as soon as possible, and then switch to an alternate-day schedule. If difficulties arise, it is preferable to administer three or even four times the daily dose on alternate days rather than merely doubling the daily dose. Once the patient is again under control, attempt to reduce this dose to the minimum. If an acute exacerbation occurs during disease progression, it may be necessary to return to a fully suppressive corticosteroid dose divided throughout the day to achieve control. Once control is achieved, the established alternate-day regimen may be attempted again.

This medication should not be administered to certain patients. For example, those who are allergic to this medication or its ingredients, or who have infections or systemic fungal infections for which effective antimicrobials are not available, may worsen their infection if this medication is used. Additionally, patients with herpes simplex, herpes zoster, and chickenpox, or those receiving live vaccines should not take this medication. This medication contains lactose, so it should be avoided in patients with lactose intolerance or related genetic disorders. Moreover, patients with glaucoma, tuberculosis, keratitis, cataract, electrolyte disorders, hypertension, thrombosis, recent surgery, a history of myocardial infarction, peptic ulcer, psychiatric disorders, osteoporosis, etc., should use this medication cautiously and only when necessary. Patients with diabetes, renal failure, congestive heart failure, hypothyroidism, fatty liver disease, myasthenia gravis, elderly patients, and those with epilepsy also require special caution. When taking this medication, side effects should be closely monitored. Symptoms such as edema, hypertension, muscle weakness, osteoporosis, gastrointestinal problems, skin changes, neurological abnormalities, endocrine anomalies, and ocular issues may occur, and immediate consultation with healthcare professionals is necessary if symptoms arise. Long-term use may lead to adrenal insufficiency; therefore, it should not be abruptly discontinued but should be gradually tapered off. The risk of infections may increase, thus care must be taken to prevent infections. Special attention should be given to exposure to chickenpox or measles, and if exposure occurs, prompt appropriate treatment should be administered. This medication can interact with various drugs, so if other medications are being taken, it is essential to inform healthcare professionals. Pregnant or breastfeeding women should consult with their doctors before use. Children and the elderly are particularly at increased risk of growth retardation or side effects, so it should be administered at the lowest effective dose with caution. Finally, it is important to regularly monitor health status through routine check-ups and blood tests while taking this medication.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral heads, steroid myopathy, muscle wasting, pathologic fracture of the pelvis, osteoporosis, vertebral compression fracture, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, dry mouth, vomiting, abdominal pain, loss of appetite, increased appetite, peptic ulcer, abdominal distension, pancreatitis, ulcerative esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, purpura, suppressed skin reaction, purpura, acne, hirsutism, hair loss, pigmentation, increased intracranial pressure, papilledema, seizures, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth suppression, latent diabetes symptoms, secondary adrenal insufficiency, hypopituitarism, reduced glucose tolerance, increased demand for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, posterior capsule cataract, secondary eye infections, retinal disorders, exophthalmos, negative nitrogen balance, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitivity reactions

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. Additionally, the medication should be kept at room temperature between 1 degree and 30 degrees Celsius for safest storage. This way, the effectiveness of the medication can be maintained for a longer duration.

Appearance

White oval tablets

Package unit

30 tablets/bottle, 500 tablets/bottle